The need for recombinant factor VIII: historical background and rationale.

Suppr

超能文献

作者信息

Hilgartner M W

机构信息

New York Hospital, Cornell University Medical Center, NY 10021.

出版信息

Semin Hematol. 1991 Apr;28(2 Suppl 1):6-9.

PMID:1908132

Abstract

摘要

相似文献

The need for recombinant factor VIII: historical background and rationale.

Semin Hematol. 1991 Apr;28(2 Suppl 1):6-9.

Development and introduction of recombinant factor VIII--a clinician's experience.

Haemophilia. 2012 Jul;18(4):483-6. doi: 10.1111/j.1365-2516.2012.02804.x. Epub 2012 Apr 19.

The history of hemophilia.

Semin Thromb Hemost. 2014 Jul;40(5):571-6. doi: 10.1055/s-0034-1381232. Epub 2014 Jun 9.

The history of haemophilia - a short review.

Thromb Res. 2014 Nov;134 Suppl 1:S4-9. doi: 10.1016/j.thromres.2013.10.020. Epub 2014 Feb 7.

Twenty years of treatment with Beriate® P.

Thromb Res. 2014 Nov;134 Suppl 1:S1-3. doi: 10.1016/j.thromres.2013.10.011. Epub 2013 Dec 21.

[Recombinant factor VIII].

Sangre (Barc). 1993 Apr;38(2):139-42.

The history of haemophilia.

J Clin Pathol. 1976 Jun;29(6):469-79. doi: 10.1136/jcp.29.6.469.

An adventure in biotechnology: the development of haemophilia A therapeutics -- from whole-blood transfusion to recombinant DNA to gene therapy.

Biotechnol Appl Biochem. 2002 Apr;35(2):141-8. doi: 10.1042/ba20010082.

On the way to virus-safe blood coagulation factor concentrates.

Semin Thromb Hemost. 2002 Apr;28 Suppl 1:15-24. doi: 10.1055/s-2002-30191.

Modern treatment of hemophilia: from the shadows towards the light.

Thromb Haemost. 1993 Jul 1;70(1):17-23.

引用本文的文献

Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells.

Biotechnol J. 2009 Feb;4(2):186-201. doi: 10.1002/biot.200800241.

Clinical perspectives of emerging pathogens in bleeding disorders.

Lancet. 2006 Jan 21;367(9506):252-61. doi: 10.1016/S0140-6736(06)68036-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The need for recombinant factor VIII: historical background and rationale.

Semin Hematol. 1991 Apr;28(2 Suppl 1):6-9.

Development and introduction of recombinant factor VIII--a clinician's experience.

Haemophilia. 2012 Jul;18(4):483-6. doi: 10.1111/j.1365-2516.2012.02804.x. Epub 2012 Apr 19.

The history of hemophilia.

Semin Thromb Hemost. 2014 Jul;40(5):571-6. doi: 10.1055/s-0034-1381232. Epub 2014 Jun 9.

The history of haemophilia - a short review.

Thromb Res. 2014 Nov;134 Suppl 1:S4-9. doi: 10.1016/j.thromres.2013.10.020. Epub 2014 Feb 7.

Twenty years of treatment with Beriate® P.

Thromb Res. 2014 Nov;134 Suppl 1:S1-3. doi: 10.1016/j.thromres.2013.10.011. Epub 2013 Dec 21.

[Recombinant factor VIII].

Sangre (Barc). 1993 Apr;38(2):139-42.

The history of haemophilia.

J Clin Pathol. 1976 Jun;29(6):469-79. doi: 10.1136/jcp.29.6.469.

An adventure in biotechnology: the development of haemophilia A therapeutics -- from whole-blood transfusion to recombinant DNA to gene therapy.

Biotechnol Appl Biochem. 2002 Apr;35(2):141-8. doi: 10.1042/ba20010082.

On the way to virus-safe blood coagulation factor concentrates.

Semin Thromb Hemost. 2002 Apr;28 Suppl 1:15-24. doi: 10.1055/s-2002-30191.

Modern treatment of hemophilia: from the shadows towards the light.

Thromb Haemost. 1993 Jul 1;70(1):17-23.

引用本文的文献

Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells.

Biotechnol J. 2009 Feb;4(2):186-201. doi: 10.1002/biot.200800241.

Clinical perspectives of emerging pathogens in bleeding disorders.

Lancet. 2006 Jan 21;367(9506):252-61. doi: 10.1016/S0140-6736(06)68036-7.